Page 25 - BH-1-2
P. 25
Brain & Heart Pemafibrate in patients with dyslipidemia
risk of bias. These RCTs exhibited a high level of quality comparable-weight studies converging toward the pooled
and, on the whole, presented a low risk of bias (Figure 21). effect size of treatment as weight increased. The pattern
The funnel plot demonstrated a symmetric distribution of indicates no evidence of publication bias.
Figure 18. Significantly lower non-high-density lipoprotein levels following treatment with pemafibrate at 0.1 mg/day.
Figure 19. Significantly lower low-density lipoprotein levels in the placebo group when compared to those treated with pemafibrate at 0.1 mg/day.
Figure 20. No difference in total cholesterol levels between groups.
Figure 21. Risk of bias summary for randomized studies (RoB 2).
Volume 1 Issue 2 (2023) 9 https://doi.org/10.36922/bh.1629
